Cargando…

Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?

Communications between clinicians and patients with idiopathic pulmonary fibrosis (IPF) have the potential to be challenging. The variable course and poor prognosis of IPF complicate discussions around life expectancy but should not prevent clinicians from having meaningful conversations about patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijsenbeek, Marlies S., Bonella, Francesco, Orsatti, Leticia, Russell, Anne-Marie, Valenzuela, Claudia, Wuyts, Wim A., Baile, Walter F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784894/ https://www.ncbi.nlm.nih.gov/pubmed/35083325 http://dx.doi.org/10.1183/23120541.00422-2021

Ejemplares similares

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models
por: Wuyts, Wim A., et al.
Publicado: (2014)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

Social Inequities and Cystic Fibrosis Outcomes: We Can Do Better
por: Oates, Gabriela R., et al.
Publicado: (2021)

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
por: Moor, Catharina C., et al.
Publicado: (2017)

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis
por: Wijsenbeek, Marlies S., et al.
Publicado: (2015)

Osteoarthritis: Can We Do Better?
por: Collins, Dylon P, et al.
Publicado: (2022)

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]
por: Orsatti, Leticia, et al.
Publicado: (2019)

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
por: Santermans, Eva, et al.
Publicado: (2019)

Malaria: How Are We Doing and How Can We Do Better?
por: Rosenthal, Philip J., et al.
Publicado: (2019)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
por: Wuyts, Wim A., et al.
Publicado: (2014)

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
por: Jouneau, Stéphane, et al.
Publicado: (2020)

Pharmacy Internships: We Can Do Better
por: Nisly, Sarah, et al.
Publicado: (2018)

Innovation in Gastroenterology—Can We Do Better?
por: Klang, Eyal, et al.
Publicado: (2022)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

The Management of Patients With Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2018)

Detecting ovarian cancer in primary care: can we do better?
por: Funston, Garth, et al.
Publicado: (2022)

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be
por: Goos, Tinne, et al.
Publicado: (2021)

Rationing care in COVID-19: if we must do it, can we do better?
por: Rockwood, Kenneth
Publicado: (2020)

We can do much better than what we did
por: Lee, Sang-Hak
Publicado: (2020)

Myocardial infarction on the ICU: can we do better?
por: Webb, Ian, et al.
Publicado: (2008)

Diagnosis of latent tuberculosis: Can we do better?
por: Al-Orainey, Ibrahim O.
Publicado: (2009)

Sebaceous gland carcinoma: Can we do better?
por: Honavar, Santosh G
Publicado: (2018)

Terminal Care: How Can We Do Better?
por: Wilkes, Erik
Publicado: (1986)

Oral cancer: We can do better - now
Publicado: (2020)

Cancer in southeast Asia: can we do better?
por: The Lancet Regional Health – Southeast Asia
Publicado: (2023)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

Update on therapeutic management of idiopathic pulmonary fibrosis
por: Tzouvelekis, Argyris, et al.
Publicado: (2015)

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey
por: Moor, Catharina C., et al.
Publicado: (2019)

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
por: Bonella, Francesco, et al.
Publicado: (2023)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Pain management following laparoscopy: Can we do better?
por: Tobias, Joseph D.
Publicado: (2013)

Labor pain relief for parturients: We can do better
por: Wang, Xian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p3m3liq7kj86nge4rka1s81mc7